These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 26833348

  • 1. Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study.
    Bhargava A, Chan V, Kimball ES, Oyer DS.
    Drugs Aging; 2016 Feb; 33(2):135-41. PubMed ID: 26833348
    [Abstract] [Full Text] [Related]

  • 2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 3. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study.
    Selam JL, Koenen C, Weng W, Meneghini L.
    Curr Med Res Opin; 2008 Jan; 24(1):11-20. PubMed ID: 18021495
    [Abstract] [Full Text] [Related]

  • 4. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 5. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 6. Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.
    Echtay A, Andari E, Atallah P, Moufarrege R, Nemr R.
    Ethn Dis; 2017 Jan 19; 27(1):45-54. PubMed ID: 28115821
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S, Maran A, Mannino D, Morano S, Lastoria G, Nicoziani P.
    Minerva Endocrinol; 2015 Dec 19; 40(4):249-58. PubMed ID: 26551483
    [Abstract] [Full Text] [Related]

  • 8. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun 19; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus.
    Yu HM, Park KS, Hong JH, Park KY, Lee JM, Ku BJ, Kim YJ, Oh TK.
    Endocrinol Metab (Seoul); 2020 Mar 19; 35(1):142-148. PubMed ID: 32207274
    [Abstract] [Full Text] [Related]

  • 10. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S, Dizdar OS, Oz Gul O, Guclu M, Unal OK, Tuncel E, Erturk E, Imamoglu S, Ersoy C.
    Prim Care Diabetes; 2014 Oct 19; 8(3):256-64. PubMed ID: 24522170
    [Abstract] [Full Text] [Related]

  • 11. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.
    Pediatr Diabetes; 2013 May 19; 14(3):196-202. PubMed ID: 23289822
    [Abstract] [Full Text] [Related]

  • 12. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study.
    Kesavadev J, Joshi SR.
    J Assoc Physicians India; 2013 Jan 19; 61(1 Suppl):28-30. PubMed ID: 24482985
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A, Patel M, Agarwal P, Lodha S, Tandon N, Magdum M, Yajnik C, Ghosh R, Walekar A.
    Diabetes Technol Ther; 2019 Nov 19; 21(11):656-664. PubMed ID: 31335198
    [Abstract] [Full Text] [Related]

  • 14. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
    Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J.
    Adv Ther; 2014 May 19; 31(5):539-60. PubMed ID: 24831915
    [Abstract] [Full Text] [Related]

  • 15. [Effectiveness and safety of initiation of once-daily insulin detemir in Chinese patients with type 2 diabetes previously treated with different quantities of oral anti-diabetic drugs: subgroup analysis of the Chinese SOLVE™ Study].
    Pan C, Ji L, Lu J, Yang W, Zhou Z, Chinese SOLVE™ Study.
    Zhonghua Nei Ke Za Zhi; 2015 Jul 19; 54(7):612-7. PubMed ID: 26359024
    [Abstract] [Full Text] [Related]

  • 16. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.
    Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, Pata P, Solerte SB, Zaccardi F.
    Expert Opin Pharmacother; 2011 Nov 19; 12(16):2449-55. PubMed ID: 21988213
    [Abstract] [Full Text] [Related]

  • 17. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E, Lang H, Roberts A.
    Diabetes Technol Ther; 2004 Oct 19; 6(5):579-88. PubMed ID: 15628811
    [Abstract] [Full Text] [Related]

  • 18. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.
    Diabetes Obes Metab; 2013 Aug 19; 15(8):729-36. PubMed ID: 23421331
    [Abstract] [Full Text] [Related]

  • 19. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.
    Vasc Health Risk Manag; 2009 Aug 19; 5(1):121-8. PubMed ID: 19436668
    [Abstract] [Full Text] [Related]

  • 20. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
    Kennedy L, Herman WH, Strange P, Harris A, GOAL AIC Team.
    Diabetes Care; 2006 Jan 19; 29(1):1-8. PubMed ID: 16373887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.